MRM Health's MH002 Receives FDA Fast Track Designation for Ulcerative Colitis Treatment
核心洞察
MRM Health (搜索)'s lead Live Biotherapeutic Product MH002 has been granted Fast Track designation by the FDA for treating mild-to-moderate ulcerative colitis (搜索), recognizing its potential to address significant unmet medical needs.
The designation was supported by Phase 2a trial results showing excellent safety and encouraging efficacy signals over eight weeks, with no adverse reactions observed and evidence of mucosal healing and clinical remission.
MH002 is composed of six well-characterized commensal bacterial strains designed to restore microbiome (搜索) balance and represents the most advanced Live Biotherapeutic Product targeting IBD-specific mechanisms.
MRM Health (搜索) announced that its lead Live Biotherapeutic Product (LBP) candidate MH002 has received Fast Track designation from the U.S. Food and Drug Administration for treating mild-to-moderate ulcerative colitis (搜索). The designation recognizes MH002's potential to address a serious medical condition with high unmet need and enables accelerated development through increased FDA interactions.
Novel Microbiome-Based Approach
MH002 represents the most advanced LBP targeting inflammatory bowel disease (搜索)-specific mechanisms and consists of a rationally designed microbial consortium of six well-characterized commensal strains. The orally administered capsule is designed to restore microbiome (搜索) balance and promote mucosal healing and immune rebalancing without immunosuppression.
"The FDA's decision to grant Fast Track designation to MH002 recognizes the potential of this promising Live Biotherapeutic Product to address the significant unmet need for innovative and more effective therapies for patients with ulcerative colitis (搜索), who have become resistant to standard treatments or for whom conventional therapies have little or no effect," said Dr. Sam Possemiers, CEO of MRM Health (搜索).
Strong Phase 2a Results Support Designation
The Fast Track designation was supported by results from a completed Phase 2a clinical trial in mild-to-moderate ulcerative colitis (搜索). Over eight weeks of treatment, MH002 demonstrated excellent safety and encouraging efficacy signals, consistent with mucosal healing and anti-inflammatory activity, recovery of microbiome (搜索) balance, and induction of clinical remission. No safety signals or adverse reactions were observed during the study.
MH002 also showed positive outcomes in an open-label study in acute pouchitis (搜索), further demonstrating its broad therapeutic potential across inflammatory bowel conditions.
Addressing Treatment Gaps
Professor Geert D'Haens, MD gastroenterologist and investigator at Amsterdam UMC (搜索), emphasized the clinical need: "While several treatments are available for UC, this is mostly the case for moderate-to-severe UC patients and many patients still fail to achieve durable remission or require treatment escalation, underscoring the need for novel treatment options."
D'Haens noted that the Fast Track designation "confirms the growing recognition of microbiome (搜索)-based therapies as a scientifically grounded strategy to restore gut homeostasis and achieve more durable remission in IBD patients."
Phase 2b Trial Plans
MH002 will be evaluated in the upcoming Phase 2b STARFISH-UC study (NCT07296315) in patients with mild-to-moderate ulcerative colitis (搜索). The trial will enroll approximately 204 patients and includes a 12-week induction phase comparing two MH002 dosing regimens versus placebo, followed by a 40-week open-label extension phase. The study will be conducted across sites in Europe and the United States, with first results expected in Q4 2027.
Company Background
MRM Health (搜索) is a clinical-stage biopharmaceutical company developing microbiome (搜索)-based Live Biotherapeutic Products for chronic inflammatory diseases. The company's CORAL platform enables the design and manufacture of disease-focused microbial consortia with enhanced efficacy and scalability. In September 2025, MRM Health closed a €55 million Series B funding round led by Biocodex.
The company will present clinical data on MH002 at the upcoming Digestive Disease Week conference in Chicago from May 2-5, 2026.